Over-prescription of short-acting β(2)-agonists for asthma in South Africa: Results from the SABINA III study

BACKGROUND: Asthma medication prescription trends, including those of short-acting β(2) -agonists (SABAs), are not well documented for South Africa (SA). OBJECTIVES: To describe demographics, disease characteristics and asthma prescription patterns in the SA cohort of the SABA use IN Asthma (SABINA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, C, Ambaram, A, Mitha, E, Abdullah, I, Abdullah, I A, Reddy, J, Trokis, J, Ramlachan, P, Govind, U, Lightfoot, K, Moodley, K, Smit, R, Beekman, M J H I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: South African Medical Association 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978998/
https://www.ncbi.nlm.nih.gov/pubmed/36874189
http://dx.doi.org/10.7196/AJTCCM.2022.v28i4.220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978998/
https://www.ncbi.nlm.nih.gov/pubmed/36874189
http://dx.doi.org/10.7196/AJTCCM.2022.v28i4.220

Ejemplares similares